Clinical Efficacy of Sequential Therapy of Statins in Treatment of Cardiovascular Diseases

2021 ◽  
Keyword(s):  
Cardiovascular Diseases ◽  
Clinical Efficacy ◽  
Sequential Therapy

In silico design of a dual TPR/TxS inhibitor for venous thromboembolism and related cardiovascular diseases

2014 ◽  
Vol 92 (4) ◽  
pp. 284-292
Author(s):  
Arpita Yadav ◽  
Abhay Krishna
Keyword(s):  
Venous Thromboembolism ◽  
Cardiovascular Diseases ◽  
Clinical Efficacy ◽  
Synergistic Effects ◽  
Docking Study ◽  
Docking Studies ◽  
Ligand Docking ◽  
Molecular Orbital Calculations ◽  
Starting Point ◽  
Drug Receptor

In recent years, many research efforts have been directed towards preventing vasoconstrictor and platelet aggregatory properties of TxA2 related to the prostaglandin cycle, as TxA2 has been implicated directly or indirectly in pathologies such as cardiovascular diseases, venous thromboembolism, and pulmonary embolism. The TxA2 antagonists and TxS inhibitors undergoing clinical trials have not shown the expected clinical efficacy. This molecular modeling and docking study explains how efficacy may be enhanced by a careful design of multitarget drugs producing synergistic effects simultaneously at different targets. A dual TPR/TxS inhibition strategy is expected to give better clinical efficacy. This study also emphasizes the importance of designing efforts based on detailed analysis of drug−receptor interactions at both targets. Ab initio HF/6-31G(d) and B3LYP/6-31G(d) molecular orbital calculations coupled with flexible ligand docking studies have led to the design of a dual TPR/TxS inhibitor starting from a naturally occurring compound bromelain, derived from pineapple extract with some known pharmacological advantages. A designed lead compound may prove to be a fruitful starting point for the development of clinically efficient drugs for venous thromboembolism and related cardiovascular diseases.

scholarly journals CLINICAL EFFICACY OF MTX-5-FU SEQUENTIAL THERAPY FOR UNRESECTABLE PANCREATIC CANCER

1998 ◽  
Vol 59 (1) ◽  
pp. 202-206
Author(s):  
Kenjiro AOGI ◽  
Akihiro SAWAMURA ◽  
Naoki HIRABAYASHI ◽  
Masahiko NISHIYAMA ◽  
Tetsuya TOGE
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Efficacy ◽  
Sequential Therapy ◽  
Unresectable Pancreatic Cancer

scholarly journals Clinical Efficacy and Mechanisms of Actions of the Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and High Risk of Cardiovascular Diseases

Kardiologiia ◽  
2021 ◽  
Vol 61 (4) ◽  
pp. 66-72
Author(s):  
S. R. Gilarevsky
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Diseases ◽  
High Risk ◽  
Clinical Efficacy ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

  The article discusses issues of reducing the risk for cardiovascular diseases (CVDs) in patients with type 2 diabetes mellitus during the treatment with modern hypoglycemic drugs, specifically glucagon-like peptide-1 receptor agonists.

scholarly journals The Clinical Efficacy of Yindanxinnaotong Soft Capsule in the Treatment of Stroke and Angina Pectoris: A Meta-Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-14 ◽  
Author(s):  
Long Cheng ◽  
Yue Liu ◽  
Xiao-bo Sun
Keyword(s):  
Cardiovascular Diseases ◽  
Angina Pectoris ◽  
Clinical Efficacy ◽  
Conventional Medicine ◽  
Meta Analysis ◽  
Effective Rate ◽  
Therapeutic Regimen ◽  
Efficacy Rate ◽  
Clinical Value ◽  
Knowledge Infrastructure

Objective. To systematically evaluate the clinical efficacy of Yindanxinnaotong (YD) soft capsule in adult patients with cardiovascular diseases (stroke and angina pectoris). Methods. We electronically searched databases including Medline, PubMed, Chinese National Knowledge Infrastructure (CNKI), Cqvip Database (VIP), and Wanfang Database for published articles of randomized controlled trials (RCTs) of YD capsule in treating stroke and angina pectoris. The meta-analysis was performed using RevMan 5.3 software. Results. 49 RCTs involving 6195 subjects with cardiovascular diseases (angina pectoris and stroke) were included. Compared with western conventional medicine (WCM) and/or other Chinese medicines, YD plus WCM therapeutic regimen could significantly improve the efficacy rate (RR = 1.21, 95% CI (1.17, 1.25), P<0.00001 for angina pectoris, RR = 1.24, 95% CI (1.18, 1.31), P<0.00001 for stroke), showing the clinical value. In addition, the therapeutic efficiency of WCM plus YD capsule regimen is better than that of WCM alone in improving CRP (MD = −2.07, 95% CI (−3.97, −0.17), P=0.03 <0.05) and TG (MD = −0.37, 95% CI (−0.52, −0.23), P<0.0001). Conclusion. YD is effective in the treatment of cardiovascular diseases (angina pectoris and stroke) in adults, and WCM plus YD therapeutic regimen can significantly improve the effective rate in the clinic.

Inflammageing in the cardiovascular system: mechanisms, emerging targets, and novel therapeutic strategies

2020 ◽  
Vol 134 (17) ◽  
pp. 2243-2262
Author(s):  
Danlin Liu ◽  
Gavin Richardson ◽  
Fehmi M. Benli ◽  
Catherine Park ◽  
João V. de Souza ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Cardiovascular System ◽  
Nlrp3 Inflammasome ◽  
Molecular Mechanisms ◽  
Molecular Targets ◽  
Therapeutic Interventions ◽  
Low Grade ◽  
Cardiovascular Research ◽  
Inflammatory Processes ◽  
Ach Receptors

Abstract In the elderly population, pathological inflammation has been associated with ageing-associated diseases. The term ‘inflammageing’, which was used for the first time by Franceschi and co-workers in 2000, is associated with the chronic, low-grade, subclinical inflammatory processes coupled to biological ageing. The source of these inflammatory processes is debated. The senescence-associated secretory phenotype (SASP) has been proposed as the main origin of inflammageing. The SASP is characterised by the release of inflammatory cytokines, elevated activation of the NLRP3 inflammasome, altered regulation of acetylcholine (ACh) nicotinic receptors, and abnormal NAD+ metabolism. Therefore, SASP may be ‘druggable’ by small molecule therapeutics targeting those emerging molecular targets. It has been shown that inflammageing is a hallmark of various cardiovascular diseases, including atherosclerosis, hypertension, and adverse cardiac remodelling. Therefore, the pathomechanism involving SASP activation via the NLRP3 inflammasome; modulation of NLRP3 via α7 nicotinic ACh receptors; and modulation by senolytics targeting other proteins have gained a lot of interest within cardiovascular research and drug development communities. In this review, which offers a unique view from both clinical and preclinical target-based drug discovery perspectives, we have focused on cardiovascular inflammageing and its molecular mechanisms. We have outlined the mechanistic links between inflammageing, SASP, interleukin (IL)-1β, NLRP3 inflammasome, nicotinic ACh receptors, and molecular targets of senolytic drugs in the context of cardiovascular diseases. We have addressed the ‘druggability’ of NLRP3 and nicotinic α7 receptors by small molecules, as these proteins represent novel and exciting targets for therapeutic interventions targeting inflammageing in the cardiovascular system and beyond.

Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial

1997 ◽  
Vol 27 (8) ◽  
pp. 860-867 ◽  
Author(s):  
V.A. VARNEY ◽  
J. EDWARDS ◽  
K. TABBAH ◽  
H. BREWSTER ◽  
G. MAVROLEON ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Specific Immunotherapy ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document